Proactiveinvestors recommends
Additional Information
Market: NYSE
Sector: Pharmaceuticals
EPIC: LLY
Latest Price: 54.14  (-1.10% Descending)
52-week High: 58.33
52-week Low: 40.15
Market Cap: 60,992.00M
1 year chart
digital-look imported chart image
1 day chart
digital-look imported chart image
Eli Lilly
www.lilly.com

Founded by Eli Lilly in 1876, it is now the 10th largest pharmaceutical company in the world.

Full Eli Lilly profile here
Pdf

Eli Lilly's Cialis gets FDA approval for two more indications

7th Oct 2011, 10:04 am by Olivia D'Orazio
Eli Lilly's Cialis gets FDA approval for two more indications

Eli Lilly and Company (NYSE:LLY) announced Friday that its Cialis drug, first intended for the treatment of erectile dysfunction (ED), has now received US FDA approval for another two indications: for the treatment of benign prostatic hyperplasia (BPH), and BPH and ED together.

The new indications cover the drug's once-daily formula, and are based on three clinical trials that evaluated nearly 2,000 men. Two of the placebo-controlled trials examined the efficacy and safety of the drug in men with BPH, while the third study evaluated the safety and efficacy of the drug in men with both ED and BPH.

BPH is a condition characterized by an enlarged prostate, which can partially or completely obstruct the urethra, causing several urinary symptoms, including difficult, painful, and frequent urination, and a higher risk of urinary tract infections.

ED, affecting approximately 50% of men between the ages of 40 and 70 years old, is a condition where the penis does not fill with enough blood to harden and expand during sexual arousal.

Eli Lilly said studies have found that these conditions can co-exist in a single patient.

Cialis, which uses tadalafil, treats ED by inhibiting the phosphodiesterase type 5 (PDE5) enzyme in the penis, relaxing the blood vessels and improving blood flow. Eli Lilly said this particular enzyme is also present in the prostate and bladder, allowing for Cialis to also treat the symptoms of BPH, though it could not define a specific mechanism pathway.

Eli Lilly's President Dave Ricks said: "These additional indications for Cialis reinforce our commitment to providing medical innovation in the area of men's health.

"We're encouraged that Cialis provides a new treatment option for men affected by both ED and the signs and symptoms of BPH."

Eli Lilly shares rose in premarket trading today, before rising another 0.75% as of 9:14 am EDT, to trade at $37.51.

No investment advice


Proactive Investors North America Inc, trades as "Proactiveinvestors USA & Canada".


You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.


You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.


From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.


You understand that we may be providing advertising and/or marketing services to companies mentioned on the site. A full list of companies that are paying for services from us, or our affiliated companies in the UK and Australia can be viewed here